|
Patent landscape, scope, and claims: |
US Patent 9,040,518: Scope of Claims, Claim Strength, and US Patent Landscape
US Patent 9,040,518 is a Markush-style composition patent with broad structural latitude in Formula I, plus claim set coverage for specific compound embodiments, crystalline form, salts, formulations, and methods for diabetes (Type I and Type II), obesity, and Type II with metformin co-administration.
What does the claim set cover (in scope terms)?
The claims cover four layers of subject matter:
- Core compounds (composition-of-matter)
- Claim 1 broadly defines a Formula I compound with layered substituent permutations at R1, R2, R3, X, Q, R4, R5, R7.
- Claims 2–14 narrow within the Markush space using additional functional restrictions.
- Claims 15–17 cover specific “The compound” embodiments (the exact identities are not provided in the prompt).
- Salts
- Claim 18: pharmaceutically acceptable salts of the Claim 1 compounds.
- Formulations
- Claim 19: pharmaceutical composition comprising the Claim 16 compound.
- Methods of use (indication)
- Claim 20: treat diabetes (Type I or Type II) or obesity in humans by administering Claim 19 composition.
- Claim 21: treat Type II diabetes.
- Claim 22: Type II diabetes with additional metformin.
The practical effect is that the patent can capture competitors even if they target the same scaffold with different substituent choices, while also preserving use claims tied to diabetes/obesity and a specific add-on therapy (metformin).
What is the actual structural breadth of Claim 1?
Claim 1 Markush framework
Claim 1 defines compounds of Formula I where the substituents vary across these axes:
- R1: H, Cl, Br, N(CH3)2, or methoxy (5 options)
- R2: H or OH (2 options)
- each R3: independently C1-6 alkyl (up to 6 carbon options, multiple independent occurrences)
- X: CH2, C(O), or CH=CH (3 options)
- Q: C0-6 alkyl (7 options including 0? treated as “C0-6,” so Q can be absent or “alkyl with 0–6 carbons,” depending on how Q is defined in the full formula)
- R4: selected from OH, SO3H, CO2H, PO3H2, CONR5R5, NR5R5, or NHC(O)CH2NR5R5 (multiple options, including charged/acidic and amide/amino linkages)
- each R5: independently from H, OH, C1-6 alkyl, C0-6 alkylCO2H, C0-6 alkylSO3H, C0-6 alkylPO3H2, and multiple substituted carboxylate/sulfonate/phosphonate variants (including acid substituent-bearing alkyl and acyl/ester-like moieties described via “C(O)C0-6alkyl…”)
- R7: C0-6alkylCO2H, C0-6alkylOH, C0-6alkylSO3H, or C0-6alkylPO3H2 (4 options)
Even without the drawn structure of Formula I, the claim is plainly designed to cover a large number of analogs by mixing:
- halogen and methoxy at R1,
- hydroxyl or hydrogen at R2,
- saturated or unsaturated linkages at X,
- flexible alkyl at Q,
- and hydrophilic acid/salt-forming groups at R4 and R5/R7 through carboxylate/sulfonate/phosphonate.
Why this breadth matters for enforcement
A Formula I Markush claim typically captures:
- structurally close analogs that differ in defined substituents, and
- salt and formulation variants,
while still being anchored to the same core scaffold and substitution logic.
Because Claim 1 explicitly permits:
- multiple ionic groups (SO3H, PO3H2, CO2H and derivatives via R5/R7),
- and multiple linker forms (X = CH2, C(O), CH=CH),
the claim set is positioned to cover different solubility profiles and different medicinal chemistry “dial settings” without stepping outside claim scope.
How do Claims 2–14 narrow the Markush space?
Layered narrowing path
Claims 2–14 impose specific selections within the Claim 1 option set:
- Claim 2: R1 is methoxy
- Claim 3: R2 is H
- Claim 4: X is CH2
- Claim 5: X is C(O)
- Claim 6: Q is C0-2 alkyl
- Claim 7: Q is absent
- Claim 8: each R3 is C2-4 alkyl
- Claim 9: each R3 is independently ethyl or n-butyl
- Claim 10: R4 is PO3H2
- Claim 11: R4 is NR5R5
- Claim 12: one R5 is H, other is selected from a list including OH, methyl, C1-4alkylCO2H, C0-2alkylSO3H, C1-2alkylPO3H2, and multiple “C(O)…” variants
- Claim 13: that other R5 is one of: CH2CO2H, CH2SO3H, CH2CH2SO3H, or CH(R7)C0-1alkyCO2H
- Claim 14: R7 is C0-1alkylCO2H or C0-2alkylSO3H
Interpretation
Claims 2–5 independently target different X substitutions (CH2 vs C(O)), while Claims 6–9 progressively constrain Q and R3 to smaller alkyl sets and specific alkyl choices (ethyl, n-butyl). Claims 10–14 lock the ionic handle strategy (R4 and the R5/R7 acid-bearing patterns), which typically correlates with solubility, salt formation, and pharmacokinetics.
The enforcement implication:
- Claim 1 is the broad net.
- Claims 2–14 represent a “coverage staircase” for analogs that medicinal chemistry teams commonly generate during optimization.
What do Claims 15–18 add (specific compound, crystalline form, salts)?
Claim 15–17: “The compound” and crystalline form
The prompt lists:
- Claim 15: “The compound”
- Claim 16: “The compound”
- Claim 17: “The compound of claim 16 wherein said compound is crystalline”
Because the identities of the “The compound” phrases are not provided in the prompt text, only the scope mechanism can be stated:
- Claim 17 creates a crystalline solid form layer over Claim 16’s identity.
- Crystalline-form claims typically strengthen enforcement against polymorph-specific or formulation-specific challenges.
Claim 18: salts
- Claim 18 covers pharmaceutically acceptable salts of the Claim 1 compound.
This is strategically important in this patent family’s chemical space because the claim set includes multiple acidic groups (CO2H, SO3H, PO3H2) that naturally form salts (Na+, K+, Ca2+, etc., depending on definition).
What does Claim 19 cover (formulation scope)?
- Claim 19: pharmaceutical composition comprising the Claim 16 compound.
This covers formulation embodiments where the active is Claim 16’s specific compound. It does not, based on the prompt, appear to extend composition coverage to the entire Claim 1 universe, because Claim 19 is explicitly tied to Claim 16.
How strong are the method claims (Claims 20–22)?
Claim 20: diabetes and obesity
- Treats diabetes mellitus (Type I or Type II) or obesity in a human by administering the Claim 19 composition.
This is a classic therapeutic indication claim. It is broad on indication (Type I + Type II + obesity) but tethered to a specific composition (Claim 19).
Claim 21: Type II diabetes
- Specifies Type II diabetes within Claim 20.
Claim 22: Type II diabetes with metformin co-administration
- Adds: method further comprises administration of metformin.
This is the most commercially relevant “stacking” language because metformin is a standard-of-care anchor for Type II diabetes. A metformin combination method claim can capture:
- add-on dosing,
- fixed or co-pack arrangements,
- and regimen-adherence labeling strategies.
Operational risk for defendants:
- if they use metformin with the patented compound for Type II diabetes, Claim 22 can be directly implicated even if they argue the base compound is used for approved therapeutic purposes already.
Claim scope map (what is inside vs outside)
Inside claim scope
Based on the claim text alone, the following types of compounds and products sit inside the patent perimeter:
- Compounds with the same Formula I core where:
- R1 is one of the enumerated options (including methoxy),
- R2 is H or OH,
- X is CH2, C(O), or CH=CH,
- Q is C0-6 alkyl (and can be absent),
- R4 is one of the enumerated acid/amino/amide-linked groups,
- and R5/R7 meet the enumerated acid-bearing patterns.
- Salts of the Claim 1 compounds.
- A pharmaceutical composition comprising the specific Claim 16 compound.
- Use of that composition for diabetes/obesity treatment in humans, and Type II diabetes with metformin.
Potentially outside claim scope
The prompt’s claim text indicates exclusions, even if the scaffold matches, when key enumerated positions are not met. Examples:
- If a competitor uses an R1 substituent not in {H, Cl, Br, N(CH3)2, methoxy}, Claim 1 is not met.
- If X is a linkage not among {CH2, C(O), CH=CH}, Claim 1 is not met.
- If R4 is not one of the enumerated acid/amino/amide patterns, Claim 1 is not met.
- If the product is a formulation that does not contain the Claim 16 compound, Claim 19 is not met (and the method claims tied to Claim 19 likewise weaken).
US patent landscape for US 9,040,518 (scope-adjacent claim space)
The prompt requests “patent landscape” for US 9,040,518, but it does not provide:
- the assignee,
- the therapeutic target (e.g., enzyme/receptor class),
- the chemical name/structure in Formula I,
- prosecution history,
- cited references,
- related family members (PCT/WO filings),
- or continuations/divisionals listed by patent number.
Without those anchors, a complete landscape cannot be constructed with hard comparisons (priority dates, citation networks, competitor portfolios, or validity exposure tied to known prior art). Under the operating constraints, no partial or speculative landscape is provided.
What can be stated from the claim text alone is the competitive “hot zone” where future design-arounds typically occur:
Landscape hot zones identifiable from the claims
- Substituent diversification at R1, X, Q, and R3
Competitors often alter:
- methoxy vs halogens vs dialkylamino at R1,
- carbonyl vs methylene at X,
- removal/variation of Q,
- and branching/sizing of alkyl at R3
without changing the core scaffold.
- Ionic handle switching at R4 and R5/R7
The claim is built around acid/phosphonate/sulfonate families and their alkyl-extended variants. Competitors commonly swap:
- CO2H vs SO3H vs PO3H2 patterns,
- and the length/identity of the alkyl spacer on the acidic substituents.
- Regimen strategy for Type II diabetes
Claim 22’s metformin co-administration creates a recognizable infringement vector for combination regimens.
These are not competing patents by number. They are the design vectors most tightly mapped by the enumerations in the claim language.
Key Takeaways
- US 9,040,518 is a scaffold-based Markush composition patent with broad structural coverage in Claim 1 and a narrower, more enforceable ladder in Claims 2–14.
- The patent adds salts (Claim 18), a specific active pharmaceutical composition (Claim 19 tied to Claim 16), and method-of-use coverage for diabetes (Type I and II), obesity, plus Type II diabetes with metformin (Claim 22).
- The enforceable strength is concentrated where claims lock:
- X (CH2 vs C(O) vs CH=CH),
- Q (including “absent”),
- R4 (notably PO3H2 and NR5R5),
- and the acid-bearing R5/R7 substitutions.
- A comprehensive US competitor patent landscape cannot be reliably generated from the prompt because the chemical identity, assignee, family members, and cited prior art are not included.
FAQs
1) Does Claim 1 cover salts directly?
No. Claim 18 separately covers pharmaceutically acceptable salts of the Claim 1 compounds.
2) Is crystalline form protected?
Yes. Claim 17 covers the crystalline form of the compound of Claim 16.
3) Do the method claims cover both Type I and Type II diabetes?
Claim 20 does, by stating Type I or Type II diabetes and obesity. Claim 21 narrows to Type II.
4) What makes Claim 22 commercially specific?
Claim 22 explicitly requires metformin co-administration in treating Type II diabetes.
5) If a competitor modifies R1, can they avoid Claim 1?
Potentially. Claim 1 restricts R1 to the listed set (H, Cl, Br, N(CH3)2, methoxy). Substituents outside that list fall outside the claim language.
References
[1] US Patent 9,040,518 (claim text provided in prompt).
More… ↓
⤷ Start Trial
|
